Viimeisin päivitys :
19/11/2024
Epilepsialääkkeet   Clonazepam  
Injektioneste
Oraaliliuos
Stabilius liuoksessa Stabilius seoksissa Tekijät, jotka vaikuttavat stabiliuteen Yhteensopivuus Antotapa Viitteet pdf
   Kemiallinen rakenne  

Kauppanimi   Kauppanimi     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Clonazepamum Puola
Iktorivil Ruotsi
Kriadex Meksiko
Ravotril Chile
Rivotril Australia, Espanja, Hollanti, Irlanti, Iso-Britannia, Kolumbia, New Zealand, Puola, Ranska, Saksa, Saudi-Arabia, Sveitsi, Unkari, Yhdistyneet arabiemiirikunnat
Viitteet   Injektioneste   Viitteet : Clonazepam  
tyyppi julkaisu
939 Lehti Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170.
1189 Lehti Nation RL, Hackett LP, Dusci LJ.
Uptake of clonazepam by plastic intravenous infusion bags and administration sets.
Am J Hosp Pharm 1983 ; 40: 1692-1693.
1246 Lehti Hooymans PM, Janknegt R, Lohman JJHM.
Comparison of clonazepam sorption to polyvinyl chloride-coated and polyethylene-coated tubings.
Pharm Weekbl [Sci] 1990 ; 12: 188-189.
1508 Lehti Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
2115 Lehti Schneider JJ, Good Ph, Ravenscroft PJ,.
Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion.
J Pain Symptom Manage 2006 ; 31, 6: 563-567.
2217 Lehti Guchelaar H.J, Hartog M.E.
De stabiliteit van clonazepaminjectievloeistof.
Ziekenhuisfarmacie 1997 ; 13, 1: 21-23.
3184 Laboratorio
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005
3617 Laboratorio Hyaluronidase (Hyalase®) - Summary of Product Characteristics
Wockhardt 2011
3728 Lehti Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3823 Lehti Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152.
3976 Lehti Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218

  Mentions Légales